These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 18808404)
41. Refractory CD20 Positive Cellular Rejection in Living Kidney Transplant: A Case Report and Review of Literature. Akl AI; Sheashaa HA; Rahim MA; El Hadedy MA; Refaie AF Exp Clin Transplant; 2019 Dec; 17(6):823-827. PubMed ID: 29534659 [TBL] [Abstract][Full Text] [Related]
42. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Billing H; Rieger S; Süsal C; Waldherr R; Opelz G; Wühl E; Tönshoff B Transpl Int; 2012 Nov; 25(11):1165-73. PubMed ID: 22897111 [TBL] [Abstract][Full Text] [Related]
43. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528 [TBL] [Abstract][Full Text] [Related]
44. New treatments for acute humoral rejection of kidney allografts. Venetz JP; Pascual M Expert Opin Investig Drugs; 2007 May; 16(5):625-33. PubMed ID: 17461736 [TBL] [Abstract][Full Text] [Related]
45. Single-dose rituximab as induction in renal transplantation. van den Hoogen MW; Hilbrands LB Transplantation; 2010 May; 89(10):1295; author reply 1295. PubMed ID: 20555227 [No Abstract] [Full Text] [Related]
46. Effect of Different Rituximab Doses on B Cell Count, Anti-A/B Antibody Titer, Graft Function, and Infectious Complications in ABO-Incompatible Renal Transplantation: A Prospective Study. Thukral S; Shinde N; Ray DS Transplant Proc; 2021 Apr; 53(3):970-975. PubMed ID: 33279260 [TBL] [Abstract][Full Text] [Related]
47. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Loupy A; Suberbielle-Boissel C; Zuber J; Anglicheau D; Timsit MO; Martinez F; Thervet E; Bruneval P; Charron D; Hill GS; Nochy D; Legendre C Transplantation; 2010 Jun; 89(11):1403-10. PubMed ID: 20386362 [TBL] [Abstract][Full Text] [Related]
48. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction. Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366 [TBL] [Abstract][Full Text] [Related]
49. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient. Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981 [TBL] [Abstract][Full Text] [Related]
51. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Zarkhin V; Li L; Sarwal MM Transplantation; 2009 Nov; 88(10):1229-30. PubMed ID: 19935379 [No Abstract] [Full Text] [Related]
52. B-cell-depleting induction therapy and acute cellular rejection. Clatworthy MR; Watson CJ; Plotnek G; Bardsley V; Chaudhry AN; Bradley JA; Smith KG N Engl J Med; 2009 Jun; 360(25):2683-5. PubMed ID: 19535812 [No Abstract] [Full Text] [Related]
53. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients. Ravichandran P; Natrajan T; Jaganathan R Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350 [TBL] [Abstract][Full Text] [Related]
54. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538 [TBL] [Abstract][Full Text] [Related]
55. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172 [TBL] [Abstract][Full Text] [Related]
57. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection. Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384 [TBL] [Abstract][Full Text] [Related]
58. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. Yoon HE; Hyoung BJ; Hwang HS; Lee SY; Jeon YJ; Song JC; Oh EJ; Park SC; Choi BS; Moon IS; Kim YS; Yang CW J Korean Med Sci; 2009 Jan; 24 Suppl(Suppl 1):S148-55. PubMed ID: 19194545 [TBL] [Abstract][Full Text] [Related]
59. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Hippen BE; DeMattos A; Cook WJ; Kew CE; Gaston RS Am J Transplant; 2005 Sep; 5(9):2248-52. PubMed ID: 16095505 [TBL] [Abstract][Full Text] [Related]